Volume 6, Issue 5 , Pages 378-385, September 2010
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss
To access this article, please choose from the options below
While funding for the neuroimaging and participant follow-up was partially obtained through a grant from GlaxoSmithKline, the authors had access to the data at all times and retain the data. Funding for the plasma lipids were obtained from National Institutes of Health grants. All authors report no conflicts of interests with regards to GlaxoSmithKline or any other organization. All participants provided informed consent and the study was approved by the Johns Hopkins University Institutional Review Board.
PII: S1552-5260(10)00099-3
doi:10.1016/j.jalz.2010.03.014
© 2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Volume 6, Issue 5 , Pages 378-385, September 2010
